FRENCH pharmaceutical giant Sanofi Pasteur declined anew the request by the Department of Health (DoH) for a refund of the used vials of the anti-dengue vaccine Dengvaxia and an indemnity fund for children who were inoculated with the drug.

“We stand firmly behind our product. Refunding the used doses of Dengvaxia would imply that the vaccine is ineffective, which is not the case. And at this time, there is also no known circumstance requiring indemnification,” Sanofi said in a statement.

Premium + Digital Edition

Ad-free access


P 80 per month
(billed annually at P 960)
  • Unlimited ad-free access to website articles
  • Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)

TRY FREE FOR 14 DAYS
See details
See details